Obesity increased Apoa2 expression in the current study, and it decreased following the empagliflozin intervention, but more research is needed to evaluate whether empagliflozin has cardioprotective effects by changing Apoa2 expression. Here, APOA2 is linked to obesity due to melanocortin 4 receptor deficiency.